


Pharmaceuticals & Biotechnology | Small Cap
Ind-Swift Laboratories exhibits a mixed financial profile. Profitability stands out as a key strength, driven by healthy margins and returns on capital. Solvency is also strong, indicating a low reliance on debt. Liquidity shows potential, supported by current and quick ratios, but is offset by a low operating cash flow ratio. However, the company has faced major issues in growth and inefficieny. Capital expenditure is low which is affecting company's growth. Overall, Ind-Swift Laboratories demonstrates solid profitability and solvency, but needs to address issues in growth and financial management to achieve a more balanced and robust financial performance.
Ind-Swift Laboratories exhibits a mixed financial profile. Profitability stands out as a key strength, driven by healthy margins and returns on capital. Solvency is also strong, indicating a low reliance on debt. Liquidity shows potential, supported by current and quick ratios, but is offset by a low operating cash flow ratio. However, the company has faced major issues in growth and inefficieny. Capital expenditure is low which is affecting company's growth. Overall, Ind-Swift Laboratories demonstrates solid profitability and solvency, but needs to address issues in growth and financial management to achieve a more balanced and robust financial performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
46.31
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
47.48
P/B RATIO
1.42
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
3.09
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
19.28
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹226.48 as on Aug 6, 2026.
The company is witnessing negative growth in revenue, operating profit, EPS, assets and net income. Revenue and operating profit growth have declined, reflecting challenges in expanding sales and maintaining profitability. A decline in asset growth indicates reduced investment in new opportunities or contraction of business activities. This could be due to various factors, including market conditions, competition, or internal inefficiencies.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 16.61 | 16.17 | 41.59 | -67.12 | 14.06 |
| Operating Profit Growth Rate | 10.38 | 13.37 | 33.62 | -106.21 | -336.84 |
| Earnings Per Share (EPS) Growth | -32.08 | -2338.89 | 1031.27 | -54.68 | -88.46 |
| Asset Growth Rate | -0.94 | 1.28 | -19.96 | -1.51 | 16.34 |
| Net Income Growth Rate | -33.33 | -2500 | 1022.92 | -53.62 | -83.6 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.81 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 44.01 | Overvalued | 73.00 | 67.39 | 48.00 |
| 5 | Sakar Healthcare Ltd | 6.89 | 67.13 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 8 | SMS Lifesciences India Ltd | 6.59 | 21.63 | Undervalued | 45.00 | 58.80 | 19.00 |
| 9 | Infinium Pharmachem Ltd | 6.42 | 26.92 | Neutral | 22.00 | 6.43 | 14.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 33.43 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -279.90 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 25.82 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 47.48 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 29.43 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Quarterly Report⬤31st Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT